Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525967 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL29945711 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL30454856 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL29945959 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23525970 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23526053 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL23526055 | 1.00 | SOS1 (0.32) | SOS1HTT | |
| SCHEMBL14977275 | 0.86 | HTT (0.42) | HTT | |
| SCHEMBL25472038 | 0.86 | HTT (0.42) | HTT | |
| SCHEMBL28934653 | 0.86 | HTT (0.42) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023121413-A1 | NOVEL BICYCLIC HETEROCYCLYL COMPOUND AND USE THEREOF | 제일약품주식회사 | 2023-06-29 | — | — | WO | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023051628-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | 上海海和药物研究开发股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | SOS1 1/4885HTT 4086/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | SOS1 1/4885HTT 4369/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | SOS1 1/4885HTT 4370/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | SOS1 1/4885HTT 4369/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | SOS1 1/4885HTT 4369/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | SOS1 1/4885HTT 4370/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | SOS1 1/4885HTT 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.